Loading
AB
Aptose Biosciences Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 26 Nov 2024.
Aptose Biosciences Inc.: what insiders have been doing
This page follows insider dealings at Aptose Biosciences Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 10 filings signed by 9 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of Aptose Biosciences Inc. has been absent for the past year. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 10 filings, this issuer sits below that mark. Since 2021, the database holds 14 purchases and 1 sale by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€509,078
14 ops. · all time
Sell Volume
€43,307
1 ops. · all time
Who traded when
BuySaleWilliam G. Rice1 buy
Since the insiders bought
- -78.6%Entry US$6.90 · Close at T+365 US$1.48
- -86.4%Entry US$83.70 · Close at T+365 US$11.40
- -59.6%Entry US$207.00 · Close at T+365 US$83.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.69
Analyst consensus
Income statement
EBITDA-US$24.2M
Net income-US$25.5M0.0% margin
Valuation
Beta0.34
Balance sheet & cash
Market capUS$4.3M
Total debtUS$28.1M
Free Cash Flow-US$22M
Profitability & ownership
ROA-181.7%
% insiders107.4%
% institutions3.9%
Last declaration on 2 July 2026
Declarations30 total
17,000 sharesCommon SharesSEC:0000912282-26-000902:0
244 sharesCommon SharesSEC:0000912282-26-000893:0
70 sharesCommon SharesSEC:0000912282-26-000894:0
222 sharesCommon SharesSEC:0000912282-26-000895:0
22 sharesCommon SharesSEC:0000912282-26-000895:1
1,122 sharesCommon SharesSEC:0000912282-26-000896:0
613,252 sharesCommon SharesSEC:0000912282-26-000897:0
14 sharesCommon SharesSEC:0000912282-26-000898:0
33 sharesCommon SharesSEC:0000912282-26-000900:0
Common SharesTSXSEDI:4742265
100,000 shares@ US$0.2018.2% of flowCommon SharesSEC:0000912282-24-000829:0
Canonical exit: 23 Feb 2025 (T+90)
17,000 shares@ US$3.14100.0% of flowCommon SharesSEC:0000912282-23-000385:0
Canonical exit: 21 Dec 2023 (T+90)
100,000 shares0Common SharesSEC:0001567619-23-001162:0
150,000 shares0Common SharesSEC:0001567619-23-001167:0
100,000 shares0Common SharesSEC:0001567619-23-001153:0
100,000 shares0Common SharesSEC:0001567619-23-001160:0
10,000 shares@ US$0.68346.5% of flowCommon SharesSEC:0001567619-22-017698:0
Canonical exit: 18 Dec 2022 (T+90)
10,000 shares@ US$0.6775100.0% of flowCommon SharesSEC:0001567619-22-017697:0
Canonical exit: 18 Dec 2022 (T+90)
10,000 shares@ US$0.96818.6% of flowCommon SharesSEC:0001567619-22-012379:0
Canonical exit: 4 Sept 2022 (T+90)
10,000 shares@ US$1.44957.0% of flowCommon SharesSEC:0001567619-21-022365:0
Canonical exit: 20 Mar 2022 (T+90)
50,000 shares@ US$1.3732.9% of flowCommon SharesSEC:0001567619-21-022331:0
Canonical exit: 16 Mar 2022 (T+90)
13,183 shares@ US$1.5216.9% of flowCommon SharesSEC:0001567619-21-022227:0
Canonical exit: 16 Mar 2022 (T+90)
120,000 shares@ US$1.15967.1% of flowCommon SharesSEC:0001567619-21-022229:0
Canonical exit: 15 Mar 2022 (T+90)
17,822 shares@ US$1.1216.9% of flowCommon SharesSEC:0001567619-21-022080:0
Canonical exit: 15 Mar 2022 (T+90)
8,643 shares@ US$2.3116.9% of flowCommon SharesSEC:0001567619-21-021215:0
Canonical exit: 24 Feb 2022 (T+90)
25 of 30 declarations
About Aptose Biosciences Inc.
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on oncology, with a particular emphasis on hematologic malignancies. For market context, the security referenced by APTOF is quoted in the U.S. OTC market, while the company has also had a historical listing on the NASDAQ under APTO; in practical terms, investors typically view Aptose as a U.S.-facing small-cap biotech with cross-border operations spanning the United States and Canada. The company describes its executive offices in Toronto and operational presence in San Diego, which reinforces its North American footprint. ([aptose.com](https://www.aptose.com/contact?utm_source=openai))
Aptose’s business model is straightforward but high-risk: it seeks to develop differentiated oral small-molecule therapies designed to address unmet medical needs in blood cancers. The company’s current core pipeline is built around two clinical-stage assets: tuspetinib, an oral myeloid kinase inhibitor, and luxeptinib, an oral dual lymphoid/myeloid kinase inhibitor. A third molecule, APTO-253, is no longer an active clinical priority. This means Aptose is not a diversified commercial biotech; rather, it is a concentrated pipeline story in which clinical validation, financing, and partnership outcomes drive the investment case. ([aptose.com](https://www.aptose.com/about?utm_source=openai))
Read moreShow less
On the product side, tuspetinib is being developed primarily for acute myeloid leukemia (AML), including frontline combination use in newly diagnosed AML patients through a TUS+VEN+AZA regimen. Management has presented tuspetinib as a genotype-agnostic oral inhibitor with the potential to improve outcomes in difficult-to-treat AML populations. Luxeptinib is positioned for B-cell malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas, while also being evaluated in myeloid tumors. The strategic logic is to target pathways linked to resistance and relapse while maintaining a tolerable safety profile that could support combination therapy. ([aptose.com](https://www.aptose.com/product-pipeline/hm43239?utm_source=openai))
Competitive positioning remains challenging. Aptose operates in highly competitive oncology markets where larger biopharma players and better-capitalized biotech companies compete for the same disease segments. The company’s differentiating thesis is not scale, but scientific focus: small molecules intended to address resistance mechanisms and support combination regimens without overlapping toxicities. That said, its commercial moat is still theoretical, as it has not yet reached marketed-product status. ([aptose.com](https://www.aptose.com/about?utm_source=openai))
Recent developments are especially important. In late 2025 and early 2026, Aptose announced an agreement with Hanmi Pharmaceutical for a take-private transaction structured through a plan of arrangement, and by March 2026 shareholders had approved the transaction while final court approval had been obtained. The company also continued to report clinical updates for tuspetinib, including ASH 2025 data highlighting response rates and tolerability in AML. In addition, Aptose disclosed very limited cash resources and reliance on advances from Hanmi to fund operations, underscoring the financial fragility typical of late-stage clinical biotech names. ([aptose.com](https://www.aptose.com/investors/news-events/press-releases/detail/343/aptose-biosciences-announces-results-of-special?utm_source=openai))
For investors in Europe, Aptose should be viewed as a speculative biotech situation rather than a traditional operating company. The upside depends on clinical execution and transaction completion, while the downside is tied to funding constraints, development risk, and the uncertainty inherent in oncology drug development. ([aptose.com](https://www.aptose.com/investors/news-events/press-releases/detail/343/aptose-biosciences-announces-results-of-special?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
